Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

CVS Sells Heroin Overdose Antidote OTC in 14 States

By Drug Discovery Trends Editor | September 25, 2015

This March 25, 2014, file photo, shows a CVS store in Philadelphia. (AP Photo/Matt Rourke)CVS has begun selling the opioid overdose reversal drug naloxone in 12 more states, according to a company statement.

A prescription won’t be required to purchase the medicine at pharmacies in the following states: Arkansas, California, Minnesota, Mississippi, Montana, New Jersey, North Dakota, Pennsylvania, South Carolina, Tennessee, Utah and Wisconsin.

Rhode Island and Massachusetts were the only states to first allow customers to buy the drug over the counter, bringing the total count to 14 states.

Naloxone, also known as Narcan, can be administered as a nasal or intravenous application to  “reverse the effects of an opioid overdose by essentially blocking the opioid receptors that are targeted by heroin and many prescription painkillers,” writes The Huffington Post.

Tom Davis, CVS’s vice president of Pharmacy Professional Practices, said in a statement this initiative will help “save lives” because more than “44,000 people die from accidental drug overdoses every year in the United States and most of these deaths are from opioids, including controlled substance pain medication and illegal drugs such as heroin.”

He added that the retailer is looking into expanding this program into other states in the future.


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE